Roche arthritis drug reduces likelihood COVID-19 patients will need ventilator, company claims
Fox Business Flash top headlines for September 17
Fox Business Flash top headlines are here. Check out what’s clicking on FoxBusiness.com.
Roche's rheumatoid arthritis treatment may reduce the likelihood that patients with COVID-19-related pneumonia would need a ventilator, the Swiss pharmaceutical company said Friday.
Continue Reading Below
People who received tocilizumab, marketed as Actemra/RoActemra, were 44% less likely to progress to the point where they would need to rely on life-support equipment, according to the company's Phase 3 EMPACTA study.
The trial was conducted in the United States, South Africa, Kenya, Brazil, Mexico and Peru.
ROCHE RAMPING UP CORONAVIRUS ANTIBODY TEST PRODUCTION TO 'UPPER-DIGIT MILLIONS': CEO